menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Johnson & Johnson Completes Acquisition of Ambrx

    BUSINESSWIRE

    J&J sees ‘opportunities’ in neuro and immunology post-Ambrx buy

    FIERCE BIOTECH

    J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

    CNBC

    Ambrx Announces Sale to Johnson & Johnson

    GLOBENEWSWIRE

    Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50

    GLOBENEWSWIRE

    Ambrx`s `reset` arrives at the last line of prostate cancer

    FIERCE BIOTECH

    Ambrx Biopharma files $300M mixed securities shelf

    SEEKING ALPHA

    Ambrx Provides Safety and Efficacy Data from Phase 1/2 APEX-01 Trial of ARX517

    GLOBENEWSWIRE

    ESMO 2023 Abstracts Available Here

    PRESS RELEASE

    Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023

    GLOBENEWSWIRE

    Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference

    GLOBENEWSWIRE

    Ambrx to Present Preliminary ARX517 First-in-Human Safety Data at ESMO 2023

    GLOBENEWSWIRE

    FDA Grants Fast Track Designation for Ambrx™s ARX517

    GLOBENEWSWIRE

    Ambrx Soars on Synthetic ADC Linker Science

    SDBJ

    Ambrx Appoints Jared Kelly as General Counsel

    GLOBENEWSWIRE

    Ambrx Announces $75 Million Market Priced Registered Offering

    GLOBENEWSWIRE

    Ambrx Appoints Stephen Glover as Chairman of its Board of Directors

    GLOBENEWSWIRE

    Ambrx to Present at JMP Securities Life Sciences Conferences

    GLOBENEWSWIRE

    Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Meeting

    GLOBENEWSWIRE

    Ambrx Raises $78 Million and Completes its ATM Program

    BUSINESSWIRE

    Ambrx to Commence Trading on Nasdaq

    BUSINESSWIRE

    ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 Achieves Positive Results

    BUSINESSWIRE

    New Ambrx CEO spies a path for ousted breast cancer med

    FIERCE BIOTECH

    ARX517 Shows Encouraging Data in Patients with Advanced Prostate Cancer

    BUSINESSWIRE

    Ambrx to host Investor Day to Discuss ARX788 and ARX517 in Cancer

    BUSINESSWIRE

    Ambrx Appoints Sandra Aung as Head of Clinical Development

    BUSINESSWIRE

    Ambrx Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Price

    BUSINESSWIRE

    Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From ARX788

    BUSINESSWIRE

    Ambrx Announces Encouraging Preliminary Safety & Efficacy Data Evaluating ARX788

    BUSINESSWIRE

    Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305

    BUSINESSWIRE

    Ambrx Biopharma Appoints Daniel O’Connor as CEO

    BIOSPACE

    Biotech layoffs continue as Ambrx cuts staff & part of pipeline to extend cash

    ENDPTS

    Ambrx dumps lead HER2 asset and lays off 15% of workforce

    FIERCEBIOTECH

    Ambrx Announces Strategic Reprioritization and Provides Corporate Update

    GLOBENEWSWIRE

    Ambrx Biopharma to Host Corporate Update Conference Call

    GLOBENEWSWIRE

    Ambrx Biopharma Reports 1H 2022 Financial Results and Provides Corporate Update

    BUSINESSWIRE

    Uncertainty at Ambrx as biotech loses CEO, reassesses pipeline

    FIERCEBIOTECH

    Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian

    BUSINESSWIRE

    Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

    BUSINESSWIRE

    Ambrx Biopharma to Present at H.C. Wainwright PCDD Conference

    BUSINESSWIRE

    Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors

    BUSINESSWIRE

    Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer

    BUSINESSWIRE

    Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences

    BUSINESSWIRE

    Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F

    BUSINESSWIRE

    Ambrx Biopharma Reports FY 2021 Financial Results; Provides Corporate Update

    BUSINESSWIRE

    Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™

    PRNEWSWIRE

    Ambrx Biopharma to Release Full Year 2021 Financial Results on Tuesday

    BUSINESSWIRE

    Ambrx Biopharma to Present at Oppenheimer’s 32nd Annual Healthcare Conference

    BUSINESSWIRE

    Ambrx Biopharma to Participate in the Cowen 42nd Annual Health Care Conference

    BUSINESSWIRE

    Ambrx Biopharma Submits IND Application for ARX305 with the U.S. FDA

    BUSINESSWIRE

    Ambrx Appoints Paul Maier to Board of Directors as Chair of Audit Committee

    BUSINESSWIRE

    Ambrx Presents Positive Data from Ongoing Phase 1 Clinical Study of ARX788

    BUSINESSWIRE

    Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at 2021

    BUSINESSWIRE

    Bristol Myers becomes latest victim of unforgiving NASH

    FIERCEBIOTECH

    Ambrx Biopharma begins dosing in Phase II trial of breast cancer treatment

    CLINICALTRIALSARENA

    Ambrx Biopharma Inc. Reports 1H 2021 Financial Results

    BUSINESSWIRE

    Ambrx Announces Positive Data on ARX788 for HER2+ Gastric Cancer at CSCO

    BUSINESSWIRE

    Ambrx Announces Positive Data on ARX788 for HER2+ Gastric Cancer at CSCO

    BUSINESSWIRE

    Ambrx to Participate at the H.C. Wainwright 23rd Annual Investment Conference

    BUSINESSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.